New and Revised Pharmacy and Medical Coverage Policies Available

Prescription process

Humana's medical and pharmacy coverage policies are based on evidence published in peer-reviewed medical literature, technology assessments obtained from independent medical research organizations, evidence-based consensus statements and evidence-based guidelines from nationally recognized professional health care organizations.

Information about medical and pharmacy coverage policies can be found at by selecting "Medical and pharmacy coverage policies" under "Resources". Medical and pharmacy coverage policies can be reviewed by name or revision date. Users also may search for a particular policy using the search box. More detailed information may be found by reviewing "How to Read a Medical Coverage Policy" and "Understanding the Medical Coverage Policy Development Process."

Below are the new and revised policies:

New pharmacy coverage policies

  • Alecensa (alectinib)
  • Daklinza (daclatasvir)
  • Esbriet (pirfenidone)
  • Portrazza (necitumumab)
  • Vraylar (cariprazine)
  • Xuriden (uridine triacetate)
  • Zepatier (elbasvir/grazoprevir)

Pharmacy coverage policies with significant revisions

  • No policies with significant revisions

New medical coverage policies

  • Genetic testing for mitochondrial disorders

Medical coverage policies with significant revisions

  • Continuous passive motion (CPM) and mechanical stretching devices
  • Femoroacetabular impingement (FAI) and iliopsoas impingement hip surgery (open or arthroscopic)
  • Glaucoma – emerging treatments
  • Negative pressure wound therapy (NPWT)
  • Prophylactic mastectomy
  • Transcatheter valve implantation

Retired medical coverage policies

  • No retired coverage policies